{"id":543288,"date":"2021-05-14T16:24:01","date_gmt":"2021-05-14T16:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543288"},"modified":"2021-05-14T16:24:01","modified_gmt":"2021-05-14T16:24:01","slug":"osteosarcoma-epidemiology-analysis-during-the-study-period-201830-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/osteosarcoma-epidemiology-analysis-during-the-study-period-201830-by-delveinsight_543288.html","title":{"rendered":"Osteosarcoma Epidemiology Analysis During the Study Period (2018-30) By DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1620965574.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Osteosarcoma Epidemiology Analysis During the Study Period (2018-30) By DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1620965574.png\" alt=\"Osteosarcoma Epidemiology Analysis During the Study Period (2018-30) By DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Osteosarcoma Epidemiology Forecast <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s Osteosarcoma report provides an in-depth understanding of the disease, historical and forecasted epidemiology, and Osteosarcoma patterns in the US, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/6b5651a06e310de3ab3f48f195708827.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&rsquo;s <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/osteosarcoma-epidemiology-forecast?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Osteosarcoma report<\/a><\/strong><span> provides an in-depth understanding of the disease, historical and forecasted epidemiology, and Osteosarcoma patterns in the US, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Crucial Highlights from the Osteosarcoma Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to DelveInsight analysts, the total Osteosarcoma incident population in the 7MM was <\/span><strong>2,228<\/strong><span> in 2020.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to the figures, the United States has the largest number of incident cases of Osteosarcoma in 2020, with more than <\/span><span><strong>1000<\/strong> <\/span><span>cases.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Males accounted for the highest Osteosarcoma prevalent cases in the US in 2020 as compared to the females.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Based on histological observations, osteosarcoma is classified into subtypes. In the United States in 2020, conventional, telangiectatic, parosteal, periosteal, and other subtypes contributed <\/span><strong>939, 47, 48, 20, and 120<\/strong><span> incident cases of Osteosarcoma, respectively.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>In 2020, Japan had <\/span><strong>199<\/strong><span> cases of Osteosarcoma, with males accounting for <\/span><strong>105<\/strong><span> and females accounting for <\/span><strong>94<\/strong><span> cases, respectively.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>To learn more request sample @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/osteosarcoma-epidemiology-forecast?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Osteosarcoma Epidemiology Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteosarcoma: Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The most common form of bone cancer, <\/span><strong>Osteosarcoma<\/strong><span> (osteogenic sarcoma), occurs in the bone&#8217;s osteoblast cells. The long bones around the knee are the most commonly affected. The upper leg, or thighbone, the lower leg, upper arm bone, or any bone in the body, including those in the pelvis, shoulder, and skull, are among the other potential locations. It can spread to surrounding tissues including tendons or muscles, as well as metastasize to other organs or bones in the body via the bloodstream.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Osteosarcoma Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Osteosarcoma Total Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Osteosarcoma Gender-Specific Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Osteosarcoma Age-Specific Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Osteosarcoma Stage-Specific Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Osteosarcoma Subtypes-Specific Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Osteosarcoma Site-Specific Incident Cases<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Gain more insights @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/osteosarcoma-treatment-market\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Osteosarcoma Treatment Approaches<\/a><\/strong><span>&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Table of Contents<\/strong>&nbsp;<\/span><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"129\" \/>\n<col width=\"495\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Key Insights<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive Summary of Osteosarcoma<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Osteosarcoma Market Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disease Background and Overview: Osteosarcoma (OS)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Osteosarcoma: Epidemiology and Patient Population<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Osteosarcoma: United States Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Osteosarcoma: EU5 Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Osteosarcoma: <\/span><span>Japan Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DelveInsight Capabilities<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disclaimer<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get in touch with our Business executive @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Osteosarcoma Market Outlook<\/a><\/strong><span> to know more&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Related Reports<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/osteoarthritis-epidemiology-forecast?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Osteoarthritis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&#8217;s <\/span><span>&#8216;Osteoarthritis &#8211; Epidemiology Forecast to 2030&#8217;<\/span><span> report delivers an in-depth understanding of the disease, historical and forecasted Osteoarthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.&nbsp;<\/span>&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=osteosarcoma-epidemiology-analysis-during-the-study-period-201830-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=osteosarcoma-epidemiology-analysis-during-the-study-period-201830-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Osteosarcoma Epidemiology Forecast DelveInsight\u2019s Osteosarcoma report provides an in-depth understanding of the disease, historical and forecasted epidemiology, and Osteosarcoma patterns in the US, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. DelveInsight&rsquo;s Osteosarcoma report provides an in-depth &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/osteosarcoma-epidemiology-analysis-during-the-study-period-201830-by-delveinsight_543288.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,406,403,404,443],"tags":[],"class_list":["post-543288","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Pharmaceuticals-Biotech","category-UK","category-US","category-Website-Blog"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543288"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543288\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}